CDH1 and breast carcinoma: It (30 μM) can also inhibit EMT-mediated migration of human NSCLC cells in vitro by targeting c-FLIP and EMT of breast cancer cells by targeting STAT3/Zeb1/E-cadherin axis [195,196].